HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Occidental (NYSE: OXY) today announced its first quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the Investor Relations section of the company’s website, oxy.com. The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Thursday, May 8, 2025, at 1 p.m. Eastern/12 p.m. Central. The conferenc ...

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), an explorer of the world’s largest undeveloped resource of critical metals for energy, defense, manufacturing and infrastructure, today announced that it will host a conference call on Wednesday, May 14, 2025, to provide an update on first quarter 2025 financial results and recent corporate developments.  First Quarter 2025 Conference Call Details  Date:Wednesday, May 14, 2025  Time:4:30 p.m. ET  A ...

Core Viewpoint - Proficient Auto Logistics, Inc. reported its financial results for Q1 2025, highlighting ongoing market challenges and the importance of market share growth and integration of recent acquisitions [1][3]. Financial Performance - Total Operating Revenue for Q1 2025 was $95.2 million, a slight increase of 0.7% from Q4 2024 but a decrease of 0.4% from Q1 2024 [2][5]. - Total Operating Loss was $(2.4) million, consistent with Q4 2024 and a significant decline from a profit of $6.5 million in Q1 2024 [2][5]. - Adjusted Operating Income was $1.2 million, up from $1.1 million in Q4 2024 but down from $6.5 million in Q1 2024 [2][5]. - Adjusted Operating Ratio improved slightly to 98.7% from 98.8% in Q4 2024 but was worse than 93.2% in Q1 2024 [2][5]. Unit Deliveries - Total Units delivered were 494,509, reflecting a 5% decrease from Q4 2024 but a 7% increase from Q1 2024 [2][5]. - Company Deliveries accounted for 163,754 units, down from 171,717 in Q4 2024 but up from 150,481 in Q1 2024 [9][12]. Revenue Metrics - Revenue per Unit for Company Deliveries was $185.38, an increase from $180.94 in Q4 2024 but a decrease from $197.38 in Q1 2024 [9][12]. - Revenue per Unit for Subhaulers was $173.14, up from $162.97 in Q4 2024 but down from $194.72 in Q1 2024 [9][12]. Balance Sheet - As of March 31, 2025, the Company had $10.9 million in cash and $79.3 million in debt, resulting in a net debt of approximately $68.4 million [14]. - The net leverage ratio was 1.9x compared to combined adjusted EBITDA of $36.3 million for the trailing twelve months [14]. Acquisitions and Market Position - The Company completed several acquisitions, including Brothers Auto Transport on April 1, 2025, and has integrated five Founding Companies since its IPO in May 2024 [3][4]. - The CEO emphasized the need for successful integration of these acquisitions to counteract market uncertainties [3]. Future Outlook - The Company plans to host an investor conference call to discuss the results and future strategies [15]. - Management is focused on improving operational performance and navigating the challenges posed by the current market environment [3][12].

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be He ...

Core Viewpoint - Telix Pharmaceuticals Limited announced the publication of its FAP-targeting therapy candidate TLX400 in the journal Thyroid, demonstrating a promising safety profile and efficacy in aggressive, radioiodine-resistant thyroid cancer [1][3]. Company Overview - Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in the United States, Brazil, Canada, Europe, and Japan [7]. Product Details - TLX400, a novel FAP-targeting therapy, has shown potential clinical utility in various oncology indications and is part of a portfolio of next-generation theranostic radiopharmaceutical candidates [2][5]. - The therapy achieved a median progression-free survival (PFS) of 29 months and overall survival (OS) of 32 months in a study involving 73 heavily pre-treated patients with radioiodine-resistant follicular thyroid carcinoma [3][5]. Clinical Insights - The study led by Dr. Sanjana Ballal reported a promising 50% partial response rate for TLX400, with manageable adverse events primarily related to hematotoxicity [5][6]. - TLX400 is differentiated by its novel structure, which allows for prolonged tumor retention while minimizing off-target uptake, addressing limitations seen in first-generation FAP-targeting compounds [5]. Competitive Landscape - The therapeutic approach for radioiodine-refractory thyroid cancer has evolved with the introduction of tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, but these treatments come with significant side effects that require careful management [4]. - TLX400's efficacy and safety profile provide a favorable comparison to TKIs, which are currently the standard of care for thyroid cancer [6].

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific an ...

The Company Intends to Delay Quarterly Earnings and Filing of 2025 Q1 Form 10-QWESTPORT, Conn., May 07, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today disclosed non-reliance on its financial statements for fiscal 2024 amid an ongoing internal investigation into its subsidiary, Lugano Holding, Inc. It also announced that it intends to delay the filing of its first quarter 2025 Form 10-Q. The Audit Committee of CODI’s Board of Directors promptly launched an investigation after CODI’s ...

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webina ...

HONG KONG, May 07, 2025 (GLOBE NEWSWIRE) -- WANG & LEE GROUP, Inc. (NASDAQ: WLGS) (“W&L”, or the “Company”), Hong Kong-based construction prime and subcontractor engaging in the installation of Electrical & Mechanical Systems, today announced that it received written notification on May 6, 2025, from The Nasdaq Stock Market LLC that it no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to the Nasdaq Listing Rule 5550(a)(2). The closing bid p ...

PLAINVIEW, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today announced its received over $35 million of orders for its AP300™ Lithography systems in recent quarters from a wide-range of IDM and OSAT customers. The orders are expected to be delivered in 2025, and are supporting capacity expansions driven by several end markets, including AI and high-performance computing. Veeco’s Advanced Packaging Lithography business is expected to deliver strong year-over-year growth in 20 ...